At Options, your journey is never one-size-fits-all we combine proven science with personal care to help you achieve real, lasting results
Another study of 125,474 people with obesity or who are overweight found that almost 47% of those with Type 2 diabetes and nearly 65% of those without diabetes stopped taking GLP-1s within a year a high rate, said Ezekiel Emanuel, a health services researcher at the University of Pennsylvania and senior author of the study
Understanding GLP-1 Injection Sites When it comes to GLP-1 injection sites, the most recommended areas generally include the abdomen, thigh, or the upper arm
This is a nuanced concern worth explaining carefully rather than dismissing outright, since it is one of the more frequently searched safety questions
GLP-1s can influence all three
Key differences include: Infections: Often accompanied by fever, warmth, and pus